665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
| Autor: | Marron, T., Segar, J., Berlin, J.D., Boccia, R., Spira, A.I., Powderly, J., Chen, C., Wainberg, Z.A., Schanzer, J.M., Glenn, J., Klumpp, K., Csiki, I., Misleh, J.G. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S523-S523 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|